Amneal Pharmaceuticals Inc (NYSE:AMRX) – Equities researchers at Piper Jaffray Companies reduced their Q4 2018 earnings per share (EPS) estimates for Amneal Pharmaceuticals in a research note issued on Wednesday, November 7th. Piper Jaffray Companies analyst D. Amsellem now anticipates that the company will post earnings of $0.29 per share for the quarter, down from their prior estimate of $0.30. Piper Jaffray Companies also issued estimates for Amneal Pharmaceuticals’ Q1 2019 earnings at $0.21 EPS, Q2 2019 earnings at $0.27 EPS, Q4 2019 earnings at $0.32 EPS, FY2019 earnings at $1.12 EPS and FY2020 earnings at $1.38 EPS.
AMRX has been the subject of a number of other reports. ValuEngine raised Amneal Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 3rd. Morgan Stanley cut their price objective on Amneal Pharmaceuticals from $26.00 to $24.00 and set an “overweight” rating for the company in a research report on Wednesday, October 3rd. Royal Bank of Canada raised Amneal Pharmaceuticals from a “sector perform” rating to an “outperform” rating in a research report on Monday, August 13th. SunTrust Banks cut Amneal Pharmaceuticals from a “buy” rating to a “hold” rating and set a $15.00 price objective for the company. in a research report on Tuesday, October 16th. Finally, Zacks Investment Research cut Amneal Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 17th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. Amneal Pharmaceuticals has a consensus rating of “Hold” and an average target price of $22.75.
Amneal Pharmaceuticals (NYSE:AMRX) last released its quarterly earnings data on Wednesday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.01. Amneal Pharmaceuticals had a negative return on equity of 8.74% and a negative net margin of 52.94%. The company had revenue of $476.50 million during the quarter, compared to analysts’ expectations of $486.01 million. Amneal Pharmaceuticals’s revenue was up 87.1% on a year-over-year basis.
In related news, SVP Nikita Shah sold 50,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Tuesday, August 21st. The stock was sold at an average price of $23.46, for a total transaction of $1,173,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Bryan M. Reasons sold 11,698 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Tuesday, August 21st. The stock was sold at an average price of $23.65, for a total value of $276,657.70. The disclosure for this sale can be found here. Company insiders own 3.20% of the company’s stock.
A number of institutional investors have recently bought and sold shares of AMRX. SG Americas Securities LLC bought a new position in Amneal Pharmaceuticals during the 2nd quarter worth $120,000. Neuburgh Advisers LLC bought a new position in Amneal Pharmaceuticals during the 2nd quarter worth $123,000. Great West Life Assurance Co. Can bought a new position in Amneal Pharmaceuticals during the 2nd quarter worth $130,000. Sei Investments Co. bought a new position in Amneal Pharmaceuticals during the 2nd quarter worth $139,000. Finally, Riverhead Capital Management LLC bought a new position in Amneal Pharmaceuticals during the 2nd quarter worth $141,000. Hedge funds and other institutional investors own 31.84% of the company’s stock.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.
See Also: Inflation
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.